DE68921895T3 - Meningococcales klasse i-aussenmembranprotein-vakzin. - Google Patents

Meningococcales klasse i-aussenmembranprotein-vakzin.

Info

Publication number
DE68921895T3
DE68921895T3 DE68921895T DE68921895T DE68921895T3 DE 68921895 T3 DE68921895 T3 DE 68921895T3 DE 68921895 T DE68921895 T DE 68921895T DE 68921895 T DE68921895 T DE 68921895T DE 68921895 T3 DE68921895 T3 DE 68921895T3
Authority
DE
Germany
Prior art keywords
class
meningococcales
membrane protein
protein vaccine
external membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68921895T
Other languages
English (en)
Other versions
DE68921895T2 (de
DE68921895D1 (de
Inventor
Robert Seid
Peter Paradiso
Jan Poolman
Peter Hoogerhout
Emmanuel Wiertz
Der Ley Peter Van
John Heckels
Ian Clarke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
De Staat Der Nederlanden Represented By Deput
Wyeth Holdings LLC
Original Assignee
Nederlanden Staat
Nederlanden Volksgezondheid Welzijn en Sport VWS
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27352237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68921895(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from NL8803111A external-priority patent/NL8803111A/nl
Application filed by Nederlanden Staat, Nederlanden Volksgezondheid Welzijn en Sport VWS, American Cyanamid Co filed Critical Nederlanden Staat
Publication of DE68921895D1 publication Critical patent/DE68921895D1/de
Publication of DE68921895T2 publication Critical patent/DE68921895T2/de
Application granted granted Critical
Publication of DE68921895T3 publication Critical patent/DE68921895T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE68921895T 1988-12-19 1989-12-19 Meningococcales klasse i-aussenmembranprotein-vakzin. Expired - Lifetime DE68921895T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NL8803111A NL8803111A (nl) 1988-12-19 1988-12-19 Multivalent meningococcen klasse i buitenmembraaneiwit vaccin.
NL8900036A NL8900036A (nl) 1988-12-19 1989-01-06 Multivalent meningococcen klasse 1 buitenmembraaneiwit vaccin.
NL8901612A NL8901612A (nl) 1988-12-19 1989-06-26 Multivalent meningococcen klasse i buitenmembraaneiwit vaccin.
PCT/US1989/005678 WO1990006696A2 (en) 1988-12-19 1989-12-19 Meningococcal class 1 outer-membrane protein vaccine

Publications (3)

Publication Number Publication Date
DE68921895D1 DE68921895D1 (de) 1995-04-27
DE68921895T2 DE68921895T2 (de) 1995-09-07
DE68921895T3 true DE68921895T3 (de) 2003-05-22

Family

ID=27352237

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68921895T Expired - Lifetime DE68921895T3 (de) 1988-12-19 1989-12-19 Meningococcales klasse i-aussenmembranprotein-vakzin.

Country Status (10)

Country Link
EP (1) EP0449958B9 (de)
JP (1) JP3436756B2 (de)
AT (1) ATE120093T1 (de)
AU (1) AU640118B2 (de)
DE (1) DE68921895T3 (de)
DK (1) DK175788B1 (de)
ES (1) ES2070312T5 (de)
FI (1) FI113009B (de)
NO (1) NO305463B1 (de)
WO (1) WO1990006696A2 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
NL9201716A (nl) * 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
AU683030B2 (en) * 1992-10-26 1997-10-30 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Immunization against (neisseria gonorrhoeae) and (neisseria meningitidis)
ES2145072T3 (es) 1993-05-13 2000-07-01 American Cyanamid Co Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
AU707131B2 (en) * 1995-08-04 1999-07-01 University Of Guelph Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
US20020028215A1 (en) 1999-08-09 2002-03-07 Jagath L. Kadurugamuwa Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
ES2217325T5 (es) * 1995-09-18 2009-04-01 United States Army Medical Research Materiel Command (Usamrmc) Metodos mejorados para la produccion de vacunas de subunidades multivalentes de proteosomas acomplejados no covalentemente.
WO1997025429A1 (en) 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
GB9611673D0 (en) * 1996-06-05 1996-08-07 Peptide Therapeutics Ltd Meningococcal vaccine
ATE252602T1 (de) 1996-08-27 2003-11-15 Chiron Corp Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
GB9701489D0 (en) 1997-01-24 1997-03-12 Auspharm Int Ltd Antigen
EP2261343A3 (de) * 1998-05-01 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
AU2003213540B8 (en) * 1998-05-29 2006-09-28 Novartis Vaccines And Diagnostic Inc. Combination meningitidis B/C vaccines
EP1741443B1 (de) * 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Kombinierte Meningitis B/C Impfstoffe
DE69934225T2 (de) * 1998-05-29 2007-09-27 Novartis Vaccines and Diagnostics, Inc., Emeryville Kombinierte meningitis b/c impfstoffe
GB9814902D0 (en) * 1998-07-10 1998-09-09 Univ Nottingham Screening of neisserial vaccine candidates against pathogenic neisseria
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6693186B2 (en) 1998-09-01 2004-02-17 Antex Biologics Inc Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
US6756493B1 (en) 1998-09-01 2004-06-29 Antex Biologics, Inc. Nucleic acid sequence and uses thereof
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
US10967045B2 (en) 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
WO2000042193A1 (en) * 1999-01-15 2000-07-20 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigen
DK1228217T3 (da) 1999-04-30 2013-02-25 Novartis Vaccines & Diagnostic Konserverede neisseria-antigener
EP1069133A1 (de) * 1999-07-13 2001-01-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Neisseria meningitidis Zusammensetzungen und ihre Verwendungen als anti-infektionsmitteln
GB9916529D0 (en) * 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
ES2543736T3 (es) * 1999-10-29 2015-08-21 Glaxosmithkline Biologicals Sa Péptidos antigénicos de Neisseria
EP1234039A2 (de) * 1999-11-29 2002-08-28 Chiron Spa 85 kda antigen von neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP1112747B1 (de) * 1999-12-28 2004-06-16 Akzo Nobel N.V. Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
DK2289545T3 (en) * 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
NZ520445A (en) * 2000-01-25 2004-02-27 Univ Queensland Proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA
PT2270030E (pt) 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
KR20030024811A (ko) 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
JP2005504718A (ja) * 2001-01-23 2005-02-17 アヴェンティス パストゥール 多価髄膜炎菌多糖−タンパク質複合ワクチン
RU2322451C2 (ru) 2001-04-17 2008-04-20 Новартис Вэксинс Энд Диагностикс, Инк. Молекулярные миметики эпитопов менингококка в, которые вызывают выработку функционально активных антител
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
US7405039B2 (en) 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
WO2003087351A1 (en) 2002-04-12 2003-10-23 Melbourne Health Hepatitis b viral variants with redused susceptibility to nucleoside analogs and uses thereof
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
AU2003274511B2 (en) 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
US7723087B2 (en) 2002-11-12 2010-05-25 The Brigham And Women's Hospital, Inc. Nucleic acid molecules for enhanced production of a bacterial polysaccharide and methods of use thereof
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
DE60332477D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CN102302776B (zh) 2003-01-30 2014-06-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
WO2005042564A1 (en) * 2003-10-20 2005-05-12 Sidney Kimmel Cancer Center Flagellin fusion proteins as adjuvants or vaccines and methods of use
SI1745075T1 (sl) 2004-04-21 2013-07-31 The Brigham And Women's Hospital, Inc. Poli-N-acetilglukozamin (PNAG/dPNAG) vezavni peptidi in postopki za njihovo uporabo
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CA2590974C (en) 2005-01-27 2017-10-03 Children's Hospital & Research Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
NZ562284A (en) 2005-04-08 2010-02-26 Melbourne Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
AU2006230802A1 (en) 2005-04-08 2006-10-12 Austin Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
GB0809659D0 (en) * 2008-05-28 2008-07-02 Univ Nottingham Polypeptides
CA2726465A1 (en) 2008-05-30 2009-12-30 Wendell David Zollinger Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
KR20110031393A (ko) 2008-07-21 2011-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
WO2010027499A2 (en) * 2008-09-05 2010-03-11 University Of Massachusetts Medical School Methods, compositions and vaccines relating to neisseria meningitidis antibodies
NZ598458A (en) 2009-08-27 2014-03-28 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
JP5960055B2 (ja) 2009-10-27 2016-08-02 ノバルティス アーゲー 改変髄膜炎菌ｆＨＢＰポリペプチド
ES2759484T3 (es) 2010-09-10 2020-05-11 Glaxosmithkline Biologicals Sa Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo
JP2012090571A (ja) * 2010-10-27 2012-05-17 Sekisui Chem Co Ltd 動物の免疫方法、免疫用組成物、抗体の製造方法、並びに、ハイブリドーマの製造方法
WO2013186753A1 (en) 2012-06-14 2013-12-19 Novartis Ag Vaccines for serogroup x meningococcus
EP3782643A1 (de) 2014-02-28 2021-02-24 GlaxoSmithKline Biologicals SA Modifizierte meningokokken-fhbp-polypeptide
US10870822B2 (en) * 2014-04-17 2020-12-22 Corning Incorporated Vessel for growth of biological entities
JP6940916B2 (ja) * 2014-07-30 2021-09-29 ゲノム プロテクション，インコーポレイテッド フラジェリン組成物および使用
EP4213943A1 (de) * 2020-09-15 2023-07-26 The University Of Montana Zusammensetzungen und verfahren zum targeting von filamentösen bakteriophagen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
WO1983003354A1 (en) * 1982-03-30 1983-10-13 Us Army Neisseria gonorrhoeae vaccine
EP0145359B1 (de) * 1983-11-21 1991-01-16 The Wellcome Foundation Limited Komplexe, Verfahren zu ihrer Herstellung und dieselben enthaltende Formulierungen
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
RU2023448C1 (ru) * 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
ATE121782T1 (de) * 1988-05-05 1995-05-15 Praxis Biolog Inc Rekombinante vakzine von flagellin.

Also Published As

Publication number Publication date
EP0449958B1 (de) 1995-03-22
DE68921895T2 (de) 1995-09-07
ES2070312T3 (es) 1995-06-01
WO1990006696A2 (en) 1990-06-28
DK175788B1 (da) 2005-02-21
AU640118B2 (en) 1993-08-19
FI912965A0 (fi) 1991-06-18
NO912369L (no) 1991-08-06
WO1990006696A3 (en) 1990-07-12
ES2070312T5 (es) 2003-05-16
NO912369D0 (no) 1991-06-18
JPH06503465A (ja) 1994-04-21
AU4821990A (en) 1990-07-10
EP0449958B2 (de) 2002-11-13
EP0449958A1 (de) 1991-10-09
EP0449958B9 (de) 2003-05-28
DK117491D0 (da) 1991-06-18
FI113009B (fi) 2004-02-27
DK117491A (da) 1991-08-15
ATE120093T1 (de) 1995-04-15
NO305463B1 (no) 1999-06-07
DE68921895D1 (de) 1995-04-27
JP3436756B2 (ja) 2003-08-18

Similar Documents

Publication Publication Date Title
DE68921895T3 (de) Meningococcales klasse i-aussenmembranprotein-vakzin.
DK0680512T3 (da) Immunogent meningokok LPS og ydermembranvesikler og vaccine deraf
FI914129A0 (fi) Nukleotidsekvens som kodar foer protein av den yttre membranen av neisseria meningitidis och an- anvaendning av naemnda protein i vaccin.
DK0561907T3 (da) Proteiner med ændrede epitoper og fremgangsmåder til fremstilling deraf
DE68924162D1 (de) Stressproteine und verwendungen dafür.
ES2063965T3 (es) Vacunas para haemophilus influenzae no tipificable.
GB2255093A (en) Hiv-1 core protein fragments
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
DE69031351T2 (de) Zubereitungen und behandlungen von pneumonia in tieren
DE68915046D1 (de) Haemophilus influenzae Typ B Polysaccharid-Aussermembranprotein-Konjugat als Impfstoff.
CA2007248A1 (en) Meningococcal class 1 outer-membrane protein vaccine
NO892015L (no) Fremgangsmaate for fremstilling av et legemiddel.
NO912823D0 (no) Fremgangsmaate for fremstilling av klasse ii-proteinet av neisseria meningitidis samt vaksiner som inneholder dette.
NO912822L (no) Fremgangsmaate for fremstilling av klasse ii-proteinet frayttermembranen til neisseria meningitidis.
DK528386A (da) Proteinabsorptionsforoegende midler
NO912824D0 (no) Fremgangsmaate for fremstilling av klasse ii-proteinet frayttermembranen til neisseria meningitidis.
ATE401341T1 (de) Vakzine enthaltend omp85 proteine von neisseria gonorrhoeae und neisseria meningitidis

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: AMERICAN CYANAMID CO., PORTLAND, ME., US DE STAAT

8327 Change in the person/name/address of the patent owner

Owner name: DE STAAT DER NEDERLANDEN, REPRESENTED BY THE DEPUT

Owner name: WYETH HOLDINGS CORP., MADISON, N.J., US